GlassScriptPhysician profile
Andrew D Mclaughlin
NPI 1114188042
$2,636.73
in general payments reported to CMS, 2019-2025
15 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.51 · 2021: $43.98 · 2022: $432 · 2023: $216 · 2024: $189 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,400 · Food and Beverage: $689 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,400.00 |
| Food and Beverage | $689.32 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,481.71 | 2023-2025 | Travoprost Intraocular Implant - Idose, Idosetr |
| Alcon Vision LLC | $362.12 | 2022-2025 | Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $202.40 | 2022-2025 | |
| Rxsight INC | $110.16 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $88.64 | 2022-2025 | Omni Surgical System |
| New World Medical,INC. | $85.25 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $68.11 | 2020-2023 | Eylea |
| Bausch & Lomb Americas INC. | $51.04 | 2022-2025 | Envista Aspire Iol, Miebo |
| Allergan, INC. | $44.33 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.98 | 2021 | |
| Dompe US, INC. | $30.18 | 2024 | Oxervate |
| Ivantis, INC | $28.27 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.51 | 2023 | |
| Ocular Therapeutix, INC. | $13.04 | 2023 | Dextenza |
| Biotissue Holdings INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.